Property Stock Forecast, Price & News
A biotechnology business called Progenity, Inc. creates and markets molecular diagnostic tools in the US. PGN-600, an oral liquid formulation of tofacitinib for the treatment of ulcerative colitis, and PGN-001, an oral version of adalimumab for the treatment of ulcerative colitis, are two biotherapeutics that the business develops for targeted oral administration.
It also creates systemic oral delivery of biotherapeutics, such as PGN-OB, a product that combines a GLP-1 receptor agonist with the Oral Biotherapeutics Delivery System (OBDS) to treat Type 2 diabetes, and PGN-OB2, a product that combines a variant of adalimumab with the OBDM to treat inflammatory conditions. Additionally, the business creates the Recoverable Sampling System, an ingestible smart capsule intended to independently locate areas in the GI.
The business also creates PIL Dx, an ingestible smart capsule meant to sample, measure, and send results, as well as Recoverable Sampling System, an ingestible smart capsule designed to autonomously detect places in the GI tract, collect, and preserve a sample for analysis.
As part of the evaluation of the OBDS for antisense oligonucleotide delivery, it has a collaboration arrangement with Ionis Pharmaceuticals. In November 2013, the business changed its name from Ascendant MDX, Inc. to Progenity, Inc. San Diego, California serves as the company’s headquarters. It was established in 2010.
NASDAQ: PROG STOCK
Progenity (prog stock) Frequently Asked Questions
SHOULD I BUY OR SELL PROGENITY STOCK RIGHT NOW?
In the last year, Progenity has received “buy,” “hold,” and “sell” evaluations from 3 Wall Street research analysts. Currently, the stock has two buy recommendations and one hold rating. Wall Street research experts concur that Progenity stock should be “moderately bought” by investors.
View the top-rated stocks or get analyst ratings for Progenity.
WHAT IS PROGENITY’S STOCK (prog stock) PRICE FORECAST FOR 2022?
For Progenity’s shares, 3 equity research analysts have provided 1-year price targets. Their predictions for the PROG stock vary from $4 to $42.00. They anticipate that Progenity’s stock will rise to $17.00 over the course of the next year, on average. This indicates a potential gain from the stock’s current price of 1,822.0 percent.
View Progenity’s price target estimates provided by analysts, or browse the best-rated companies by Wall Street analysts.
WHEN IS PROGENITY’S (prog stock) NEXT EARNINGS DATE?
The next Progenity quarterly earnings report is expected to be released on August 10th, 2022.
